EurekaMag
+ Most Popular
Cunninghamia lanceolata plantations in China
Mammalian lairs in paleo ecological studies and palynology
Studies on technological possibilities in utilization of anhydrous milk fat for production of recombined butter-like products
Should right-sided fibroelastomas be operated upon?
Large esophageal lipoma
Apoptosis in the mammalian thymus during normal histogenesis and under various in vitro and in vivo experimental conditions
Poissons characoides nouveaux ou non signales de l'Ilha do Bananal, Bresil
Desensitizing efficacy of Colgate Sensitive Maximum Strength and Fresh Mint Sensodyne dentifrices
Administration of fluid by subcutaneous infusion: revival of a forgotten method
Tundra mosquito control - an impossible dream?
Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population
Geochemical pattern analysis; method of describing the Southeastern limestone regional aquifer system
Incidence of low birth weights in a hospital of Mexico City
Tabanidae
Graded management intensity of grassland systems for enhancing floristic diversity
Microbiology and biochemistry of cheese and fermented milk
The ember tetra: a new pygmy characid tetra from the Rio das Mortes, Brazil, Hyphessobrycon amandae sp. n. (Pisces, Characoidei)
Risk factors of contrast-induced nephropathy in patients after coronary artery intervention
Renovation of onsite domestic wastewater in a poorly drained soil
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Systolic blood pressure in a population of infants in the first year of life: the Brompton study
Haematological studies in rats fed with metanil yellow
Studies on pasteurellosis. I. A new species of Pasteurella encountered in chronic fowl cholera
Dormancy breaking and germination of Acacia salicina Lindl. seeds
therapy of lupus nephritis. a two-year prospective study

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake


Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake



Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 40(5): 762-767



ISSN/ISBN: 0161-5505

PMID: 10319747

Scintigraphy with (111In-diethylenetriamine pentaacetic acid0-D-Phe1)-octreotide (DTPAOC) is used to demonstrate neuroendocrine and other somatostatin-receptor-positive tumors. Despite encouraging results, this 111In-labeled compound is not well suited for peptide-receptor-mediated radiotherapy of somatostatin-receptor-positive tumors. Another somatostatin analog, (1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid0, D-Phe1, Tyr3)-octreotide (DOTATOC), can be labeled with the beta-emitter 90Y in a stable manner. Methods: We compared the distribution, kinetics and dosimetry of 111In-DTPAOC and 111In-DOTATOC in eight patients to predict the outcomes of these parameters in patients who will be treated with 90Y-DOTATOC. Results: Serum radioactivity levels for the radiopharmaceuticals did not differ significantly 2-24 h after injection (P > 0.05). Up to 2 h postinjection they were slightly, but significantly, lower after administration of 111In-DOTATOC (P < 0.01 at most time points). The percentage of peptide-bound radioactivity in serum did not differ after administration of either compound. Urinary excretion was significantly lower after administration of 111In-DOTATOC (P < 0.01). The visualization of known somatostatin-receptor-positive organs and tumors was clearer after administration of 111In-DOTATOC than after administration of 111In-DTPAOC. This was confirmed by significantly higher calculated uptakes in the pituitary gland and spleen. The uptake in the tumor sites did not differ significantly (P > 0.05), although in three of the four patients in whom tumor uptake could be calculated, it was higher after administration of 111In-DOTATOC. Conclusion: The distribution and excretion pattern of 111In-DOTATOC resembles that of 111In-DTPAOC, and the uptake in somatostatin-receptor-positive organs and most tumors is higher for 111In-DOTATOC. If 90Y-DOTATOC shows an uptake pattern similar to 111In-DOTATOC, it is a promising radiopharmaceutical for peptide-receptor-mediated radiotherapy in patients with somatostatin-receptor-positive tumors.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010355821

Download citation: RISBibTeXText

Related references

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients : Biodistribution, kinetics, organ and tumor uptake. The Journal of Nuclear Medicine (1978) 40(5): 762-767, 1999

Quantitative in vivo uptake kinetics of -octreotide in tumor bearing rats as measured by PET A comparison with -DFO-octreotide and -DTPA-octreotide. Journal of Nuclear Medicine 36(5 Suppl): 113P-114P, 1995

Bone marrow dose results in peptide receptor radionuclide therapy with 90Y-DOTA-Tyr3-Octreotide, 111In-DTPA-Octreotide and 177Lu-DOTA-Octreotate Importance of dosimetry model. Journal of Nuclear Medicine 43(5 Suppl): 90P, 2002

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Nuclear Medicine Communications 29(3): 283-290, 2008

Development of receptor-based radiopharmaceuticals using carrier-free promethium-149 Syntheses, in vitro stability studies, and in vivo biodistribution studies of DTPA, DOTA, and DTPA-Octreotide complexes. Journal of Nuclear Medicine 41(5 Suppl): 246P, 2000

111 In-DTPA-d-Phe -1 -Asp 0 -d-Phe 1 -octreotide exhibits higher tumor accumulation and lower renal radioactivity than 111 In-DTPA-d-Phe 1 -octreotide. Nuclear Medicine and Biology 54: 18-26, 2017

Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. Cancer BioTherapy and Radiopharmaceuticals 20(2): 231-236, 2005

68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®). Molecular Imaging and Biology 13(3): 583-593, 2011

Biodistribution of a new chelated somatostatin analogue, -octreotide Comparison with -octreotide in humans. Journal of Nuclear Medicine 38(5 Suppl): 103P, 1997

Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 33(5): 652-658, 1992

Organ and tumor dosimetry of 177Lu-DOTA-Tyr3-octreotate and 90Y-DOTA-Tyr3-octreotide A preliminary study in 2 patients. Journal of Nuclear Medicine 43(5 Suppl): 316P, 2002

Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 46(9): 1561-1569, 2005

PET-pharmacokinetics of 18F-octreotide: A comparison with 67Ga-DFO- and 86Y-DTPA-octreotide. Nuclear Medicine and Biology 24(4): 275-286, 1997

Biodistribution of [111In-DTPA-D-Phe1]-octreotide in dogs: uptake in the stomach and intestines but not in the spleen points towards interspecies differences. Nuclear Medicine and Biology 30(3): 225-232, 2003

Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man. Bioorganic and Medicinal Chemistry Letters 8(10): 1207-1210, 1998